ASRA Pain Medicine Update

Learning Objectives

1. Understand the bidirectional relationship between chronic pain and psychiatric comorbidities, including depression, anxiety, and sleep disorders.
   
2. Identify evidence-based behavioral and pharmacologic interventions that serve as psychiatric adjuncts in chronic pain management.
   
3. Recognize how psychosocial and cultural factors influence pain perception, treatment adherence, and recovery.
   
4. Apply a structured approach to integrating psychological, pharmacologic, and social strategies across outpatient and inpatient settings.
   
5. Discuss ethical, communication, and interprofessional collaboration strategies for equitable and compassionate care in patients with psychiatric comorbidity and chronic pain.
   

Case Stem

Ms. R, a 52-year-old woman with chronic low-back pain and bilateral knee osteoarthritis, presents to an outpatient pain clinic for evaluation. Her pain began after a workplace injury seven years ago and has gradually worsened. She reports poor sleep, fatigue, and decreased concentration, describing her pain as constant and “never shutting off,” rated 7/10 at rest. Her primary-care physician recently initiated duloxetine 30 mg daily for pain and mood, but she reports minimal relief.

Her medical history includes hypertension, type 2 diabetes, and generalized anxiety disorder. She works part-time as a receptionist and cares for her elderly mother. Socially, she reports loneliness since divorce and less engagement with her church community. She denies substance use.

Her Pain Catastrophizing Scale (PCS) score is 32 (high) and Patient Health Questionnaire–9 (PHQ-9) = 15 (moderate depression). She takes oxycodone 5 mg three times daily as prescribed but worries she is “getting used to it.” Physical therapy attendance has been inconsistent due to fear of flares.

1. How do psychiatric comorbidities contribute to pain chronification and treatment resistance?

Psychiatric comorbidities (particularly depression, anxiety, and sleep disorders) are among the strongest predictors of pain persistence and disability. Pain and emotional distress share overlapping neurobiologic circuits, especially within the limbic system and anterior cingulate cortex. The bidirectional relationship between mood and pain creates a cycle in which anxiety and depression heighten pain perception, while chronic pain reinforces helplessness and catastrophizing.^1,2,3

Sleep disturbance is another key factor; poor sleep quality exacerbates pain and predicts next-day intensity and distress.¹ Pain catastrophizing (rumination, magnification, and helplessness) amplifies both sensory and emotional pain experience.² Identifying and addressing these psychological factors early can prevent treatment resistance and enhance responsiveness to multimodal therapy.³

2. How should psychiatric screening be integrated into the pain evaluation process?

Tools such as the PHQ-9 for depression and GAD-7 for anxiety assess affective distress, while the PCS quantifies maladaptive cognitive responses to pain and predicts outcomes.² Screening should include sleep quality, trauma history, and coping style. Cognitive changes from chronic pain or opioids also warrant attention. In older or hospitalized patients, delirium tools such as the Confusion Assessment Method (CAM) or Intensive Care Delirium Screening Checklist (ICDSC) can identify acute cognitive changes that worsen pain behaviors.⁴

Psychiatric screening guides therapeutic triage: patients with severe depression or suicidality need urgent psychiatric evaluation, whereas those with mild distress may benefit from behavioral coaching, sleep hygiene, or mindfulness interventions.

3. What outpatient behavioral interventions improve pain control and quality of life?

Behavioral interventions are cornerstone adjuncts in chronic pain treatment. Cognitive-behavioral therapy (CBT) targets maladaptive thoughts such as catastrophizing and fear-avoidance, helping patients reinterpret pain sensations and re-engage in activity.⁵ Acceptance and Commitment Therapy (ACT) emphasizes psychological flexibility, such as pursuing valued goals despite pain.

Mindfulness-based stress reduction (MBSR) and relaxation training reduce sympathetic arousal and have demonstrated efficacy in lowering acute and chronic pain intensity while improving mood and sleep.^5,6 Guided imagery and diaphragmatic breathing are easily introduced during clinic visits.

Educational interventions further enhance efficacy. Providing structured information on pain mechanisms, expected recovery, and non-opioid strategies reduces anxiety and postoperative opioid use. When combined with multimodal pharmacologic therapy, these behavioral strategies improve function, restore a sense of control, and in perioperative and subacute pain settings have been associated with reduced analgesic requirements.^7,8,9

4. How do social and cultural factors influence the psychiatric and pain experience?

Pain is profoundly shaped by social context, culture, and language. Strong social support improves adherence and reduces perceived pain, while social isolation correlates with higher pain interference and depression.^10,11 Cultural background influences pain expression and help-seeking behavior. Language barriers may intensify mistrust or miscommunication.^12,13

Clinicians should employ trained interpreters and culturally tailored materials. Spiritual or religious frameworks may influence coping and should be incorporated when relevant. Reconnecting Ms. R with her social networks can alleviate distress and enhance recovery.

5. What pharmacologic options address both psychiatric and pain dimensions?

Pharmacologic strategies bridging psychiatric and analgesic effects are particularly valuable. Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine and venlafaxine are commonly used to address co-occurring pain and mood symptoms, with particular utility in neuropathic and musculoskeletal pain. Tricyclic antidepressants (TCAs) like amitriptyline and nortriptyline provide analgesia but have anticholinergic and cardiac limitations in older adults.

Alpha-2 adrenergic agonists (e.g., clonidine, dexmedetomidine) decrease noradrenergic outflow, may reduce opioid requirements in select perioperative and inpatient settings, and provide anxiolysis, especially in perioperative or refractory pain.¹⁵ In patients with insomnia, agents such as trazodone or mirtazapine may restore sleep and improve mood. Anticonvulsants (e.g., gabapentin, pregabalin) aid neuropathic pain but require caution for sedation or mood effects. Integrating psychopharmacology with behavioral approaches produces synergistic benefit and reduces opioid dependence.

Case Progression #1: Transition to Inpatient Setting

Two months later, Ms. R undergoes knee arthroscopy. Postoperatively she experiences severe pain despite regional block and multimodal therapy. She becomes tearful, reports panic attacks, and requests IV opioids, expressing fear that “no one believes my pain.” The surgical team consults pain and psychiatry services.

6. How should psychiatric adjuncts be incorporated in inpatient management of complex pain?

Hospitalization introduces stressors (e.g., loss of control, disrupted sleep, stigma about opioid use) that heighten pain. Early psychiatric involvement centers on validation, reassurance, and anxiety reduction rather than dose escalation. Non-opioid infusions such as ketamine (which at subanesthetic doses may provide both analgesic and rapid antidepressant effects) and lidocaine are commonly used in complex pain states; α₂-agonists can diminish central sensitization and opioid burden.¹⁵

Nonpharmacologic strategies such as relaxation training and guided imagery help regulate distress. Delirium screening with CAM or ICDSC is essential in older or complex patients.⁴ Baseline antidepressants should be continued; abrupt benzodiazepine withdrawal must be avoided. Differentiating psychological distress from misuse prevents undertreatment and mistrust. Collaboration among psychiatry, anesthesia, and nursing ensures compassionate, consistent messaging.

7. How can clinicians promote adherence and prevent relapse or chronicity post-discharge?

Discharge is a vulnerable phase. Key principles are continuity, education, and empowerment. Structured follow-up with pain-psychiatry teams reinforces adherence. Written agreements emphasizing functional goals over complete pain elimination help recalibrate expectations and support adherence.

Education on sleep hygiene, graded activity, and mood monitoring reduces relapse risk. Behavioral “booster” sessions or tele-CBT maintain progress. For socially isolated patients, group-based rehabilitation or peer support restores accountability.^10,11

Medication adjustments require monitoring for side effects or withdrawal. Coordination with primary-care and mental-health providers ensures unified messaging. Self-monitoring of mood and sleep diaries fosters insight and self-efficacy, key predictors of durable improvement.

8. What ethical and communication principles guide care in psychiatric–pain overlap?

Care must balance autonomy, beneficence, non-maleficence, and justice. Clinicians should respect patients’ pain reports while applying evidence-based limits to prevent harm. Implicit bias (especially toward “difficult” or “drug-seeking” patients) can lead to undertreatment and eroded trust.

Shared decision-making and motivational interviewing strengthen alliance and readiness for change. Documentation of risk-benefit discussions protects both patient and provider. Cultural competence and language accessibility are ethical imperatives; patient education aligned with worldview promotes adherence and dignity.^12,13 Compassionate communication and empathy remain the foundation of equitable chronic-pain management.

Case Progression #2: Outpatient Follow-Up

At three-month follow-up, Ms. R reports restorative sleep, improved mood, and renewed participation in physical therapy. Duloxetine increased to 60 mg daily; she practices relaxation nightly and attends a local support group. Oxycodone use is now rare.

“It’s still there,” she says, “but it doesn’t control me anymore.” The team discusses maintenance, gradual tapering, and continued psychotherapy.

Conclusion and Key Takeaways

• Pain and psychiatric comorbidities are inseparable; addressing mood, anxiety, and sleep is essential for effective analgesia.^1,2,3
  
• Behavioral interventions such as CBT, mindfulness, and education improve function and reduce opioid reliance.^5,6,7,8,9
  
• Social and cultural context determine coping and recovery; isolation and stigma worsen outcomes.^10,11,12,13
  
• Psychopharmacologic adjuncts (e.g., SNRIs, TCAs, α₂-agonists) provide dual benefit when integrated thoughtfully.^14,15
  
• Inpatient management should emphasize continuity, anxiety modulation, and interprofessional coordination.^4,15
  
• Ethical, communication-centered care grounded in empathy and cultural competence underlies all successful chronic-pain management.
  

References

1. Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a path forward. J Pain 2013;14(12):1539-52. doi:10.1016/j.jpain.2013.08.007
   
2. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: development and validation. Psychol Assess 1995;7(4):524-32. doi:10.1037/1040-3590.7.4.524
   
3. Wiech K, Tracey I. The influence of negative emotions on pain: behavioral, brain imaging, and clinical studies. Neuroimage 2009;47(3):987-94. doi: 10.1016/j.neuroimage.2009.05.059.
4. Inouye SK, Westendorp RGJ, Saczynski JS. Delirium in elderly people. Lancet 2014;383(9920):911-22. doi:10.1016/S0140-6736(13)60688-1
   
5. Garland EL, Froeliger B, Howard MO. Mindfulness training targets neurocognitive mechanisms of addiction at the attention-appraisal-emotion interface. Front Psychiatry  2013;4:173. doi:10.3389/fpsyt.2013.00173
   
6. Zeidan F, Grant JA, Brown CA, McHaffie JG, Coghill RC. Mindfulness meditation-related pain relief: evidence for unique brain mechanisms in the regulation of pain. J Neurosci 2012;32(18):165-73. https://doi.org/10.1016/j.neulet.2012.03.082
   
7. Powell R, Scott NW, Manyande A, et al. Psychological preparation and postoperative outcomes for adults undergoing surgery under general anaesthesia. Cochrane Database Syst Rev 2016;(5):CD008646. doi:10.1002/14651858.CD008646.pub2
   
8. Walker EMK, Bell M, Cook TM, Grocott MPW, & Moonesinghe SR. Patient reported outcome of adult perioperative anaesthesia in the United Kingdom: a cross-sectional observational study. Br J Anaesth. 2016 Jun 12;117(6):758-66. doi: 10.1093/bja/aew381. Erratum in: Br J Anaesth. 2017 Sep 1;119(3):552. doi: 10.1093/bja/aew471
   
9. McDonald S, Page MJ, Beringer K, et al. Preoperative education for hip or knee replacement. Cochrane Database Syst Rev 2014;(5):CD003526. doi:10.1002/14651858.CD003526.pub3
   
10. Uchino BN. Social support and health: a review of physiological processes potentially underlying links to disease outcomes. J Behav Med 2006;29(4):377-87. doi:10.1007/s10865-006-9056-5
    
11. Cacioppo JT, Hawkley LC. Social isolation and health, with an emphasis on underlying mechanisms. Perspect Biol Med 2003;46(3 Suppl):S39-S52. doi:10.1353/pbm.2003.0063
    
12. Green CR, Anderson KO, Baker TA, et al. The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Med 2003;4(3):277-94. doi:10.1046/j.1526-4637.2003.03034.x
    
13. Hsieh, E. Not Just “Getting by”: factors influencing providers’ choice of interpreters. J Gen Intern Med 2015;30:75–82. doi:10.1007/s11606-014-3066-8 
14. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56(4):1336-44. doi:10.1002/art.22433
15. Smith H, Elliott J. Alpha(2) receptors and agonists in pain management. Curr Opin Anaesthesiol 2001;14(5):513-8. doi:10.1097/00001503-200110000-00009